Weng Xingbei, Shi Qiucheng, Wang Sheng, Shi Yubo, Sun Dinghe, Yu Yunsong
Department of Laboratory Medicine, Ningbo Hospital, Zhejiang University School of Medicine, Ningbo, China.
Department of Laboratory Medicine, Ningbo First Hospital, Ningbo, China.
Can J Infect Dis Med Microbiol. 2020 Jul 8;2020:5626503. doi: 10.1155/2020/5626503. eCollection 2020.
Carbapenem-resistant (CRKP) was epidemic around the world and become a global threat to public health. The most important carbapenem-resistant mechanism is producing carbapenemases, especially carbapenemase (KPC), which is prevalent in the international clonal complex CC11. The high-risk multidrug-resistant CC11 is widespread worldwide, and KPC-producing and (New Delhi metallo) NDM-producing strains had been reported in this clonal complex before; moreover, cases with the CC11 strain faced more severe forms of drug resistance and treatment challenges than other clonal complexes. In this study, we identified an OXA-232-producing ST437 isolate in China, which belonged to CC11. The isolate was resistant to -lactams, aminoglycosides, and fluoroquinolones but susceptible to fosfomycin, tigecycline, and colistin. The gene was located on a 6141 bp ColKP3-type nonconjugative plasmid, and the plasmid was transformed by chemical transformation successfully. This is the first report of OXA-232-producing ST437 in China, a new clone of high-risk multidrug-resistant CC11.
耐碳青霉烯类肺炎克雷伯菌（CRKP）在全球范围内流行，已成为对公共卫生的全球性威胁。最重要的耐碳青霉烯类机制是产生碳青霉烯酶，尤其是碳青霉烯酶（KPC），其在国际克隆复合体CC11中普遍存在。高风险多重耐药的CC11在全球广泛传播，此前该克隆复合体中已报道过产KPC和（新德里金属β-内酰胺酶）NDM的菌株；此外，CC11菌株感染病例面临比其他克隆复合体更严重的耐药形式和治疗挑战。在本研究中，我们在中国鉴定出一株产OXA-232的ST437分离株，其属于CC11。该分离株对β-内酰胺类、氨基糖苷类和氟喹诺酮类耐药，但对磷霉素、替加环素和黏菌素敏感。该基因位于一个6141bp的ColKP3型非接合性质粒上，并且该质粒通过化学转化成功实现了转化。这是中国首次报道产OXA-232的ST437，它是高风险多重耐药CC11的一个新克隆。
